Defibrotide for severe COVID-19 in adults
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests defibrotide to see if it improves outcomes in people hospitalized with severe COVID-19. You may be considered if you have confirmed infection, abnormal chest imaging, and meet specific severity and safety requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You currently have COVID-19 confirmed by a positive PCR test
- Your chest imaging shows problems in both lungs
- Your doctor expects you could live at least 24 hours
- Your COVID severity matches a WHO score from 4 to 7
- If you are on blood thinners, the type and timing must fit the study plan, and any clot-focused dosing may be allowed only if there is no bleeding after at least 24 hours
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called AVM0703 to see if it can help people with severe lung damage caused by COVID-19 or influenza. It focuses on patients who need a breathing machine or ECMO because their lungs are failing.
This early-stage study tests COVID-19 treatments in people who have recently developed symptoms and who test positive for the virus. It aims to find safer, more effective options for preventing worsening disease, especially in higher-risk groups.
This study tests an antiviral medicine called FS-1 (brand name Efesovir) in adults hospitalized with COVID-19 who have risk factors for severe illness. The goal is to see if the drug can help them recover faster or avoid more serious complications.
This study tests whether a higher dose of defibrotide can help patients who develop SOS/VOD after a stem cell transplant and haven't gotten better with the standard dose. SOS/VOD is a liver condition that sometimes also affects the kidneys or lungs.
This trial tests a stem cell transplant from a half-matched donor using a strong conditioning regimen and a drug called defibrotide to protect organs. It aims to cure sickle cell disease in patients who have had serious complications like stroke, chest syndrome, or frequent pain episodes.
This trial tests whether Codivir can help people hospitalized with moderate COVID-19 recover better than a placebo (inactive pill). It will compare outcomes while participants receive standard hospital care.
Hear when a new Covid19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.